Fate Therapeutics, Inc. (FATE) Earnings History
Annual and quarterly earnings data from 2011 to 2025
Loading earnings history...
FATE EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
FATE Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -2222.4% | -2051.1% |
| 2024 | 100.0% | -1542.6% | -1366.5% |
| 2023 | -147.4% | -299.9% | -253.3% |
| 2022 | 85.7% | -320.2% | -292.5% |
| 2021 | 89.5% | -388.6% | -379.9% |
Download Data
Export FATE earnings history in CSV or JSON format
Free sign-in required to download data
Fate Therapeutics, Inc. (FATE) Earnings Overview
As of May 8, 2026, Fate Therapeutics, Inc. (FATE) reported trailing twelve-month net income of -$136M, reflecting +29.9% year-over-year growth. The company earned $-1.15 per diluted share over the past four quarters, with a net profit margin of -2051.1%.
Looking at the long-term picture, FATE's historical earnings data spans multiple years. The company achieved its highest annual net income of -$13M in fiscal 2011.
Fate Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CRSP (-$569M net income, -16569.8% margin), NTLA (-$413M net income, -609.9% margin), BEAM (-$65M net income, -57.2% margin), FATE has outperformed on profitability metrics. Compare FATE vs CRSP →
FATE Earnings vs Peers
Earnings metrics vs comparable public companies
FATE Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$136M | +26.8% | -$148M | $-1.15 | -2051.1% | -2222.4% |
| 2024 | -$186M | -15.7% | -$210M | $-1.64 | -1366.5% | -1542.6% |
| 2023 | -$161M | +42.9% | -$191M | $-1.64 | -253.3% | -299.9% |
| 2022 | -$282M | -32.8% | -$308M | $-2.91 | -292.5% | -320.2% |
| 2021 | -$212M | -22.4% | -$217M | $-2.24 | -379.9% | -388.6% |
| 2020 | -$173M | -76.7% | -$128M | $-2.10 | -551.6% | -407.5% |
| 2019 | -$98M | -47.4% | -$101M | $-1.43 | -919.0% | -943.1% |
| 2018 | -$67M | -55.1% | -$67M | $-1.19 | -1405.0% | -1415.4% |
| 2017 | -$43M | -28.4% | -$42M | $-1.02 | -1046.1% | -1025.9% |
| 2016 | -$33M | -11.6% | -$32M | $-1.05 | -760.2% | -726.1% |
See FATE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FATE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FATE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFATE — Frequently Asked Questions
Quick answers to the most common questions about buying FATE stock.
Is FATE growing earnings?
FATE EPS is $-1.15, with earnings growth accelerating to +29.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-136M.
What are FATE's profit margins?
Fate Therapeutics, Inc. net margin is -2051.1%, with operating margin at -2222.4%. Below-average margins reflect competitive or cost pressures.
How consistent are FATE's earnings?
FATE earnings data spans 2011-2025. The accelerating earnings trend is +29.9% YoY. Historical data enables comparison across business cycles.